Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Susan L. Cohn

TitleProfessor
InstitutionUniversity of Chicago
DepartmentPediatrics
AddressChicago IL 60637
Phone+1 (773) 702-2571
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Our long-term research interest is to improve the outcome for children with neuroblastoma. We are conducting laboratory-based research focused on understanding the cellular pathways that drive clinically aggressive neuroblastoma growth in order to identify actionable mutations that can be targeted and tested in clinical trials. We have an active collaboration with Drs. Chuan He and Lucy Godley investigating the epigenetic landscape of neuroblastoma. We are also collaborating with Dr. Sam Volchenboum and Dr. Robert Grossman to build an International Neuroblastoma Risk Group (INRG) Data Commons that contain phenotype data on a large cohort of neuroblastoma patients diagnosed around the world. The database was built with technology that allows connections with other databases that contain clinical and genomic information on patients with neuroblastoma diagnosed around the world. These data are available to investigators for data mining studies. Currently, clinical information on >20,000 patients with neuroblastoma are included in the INRG Data Commons. More than 20 research projects have been performed, and many of which would not have been possible with smaller patient cohorts.


    Collapse Biography 
    Collapse education and training
    Northwestern University, Evanston, IllinoinsBA1976Biology
    University of Illinois Medical School, Chicago, IllinoisMD1980
    Michael Reese Hospital and Medical Center, Chicago, Illinois1984Resident in Pediatrics
    Northwestern University, Chicago, Illinois1987Fellow in Pediatric Hematology/Oncology
    Collapse awards and honors
    2014Senior Faculty Scholar in the Bucksbaum Institute for Clinical Excellence, University of Chicago
    2012Association for Women in Science (AWIS) Chicago Innovator Award
    2012 - 2015Treasurer, American Society of Clinical Oncology
    2012Pritzker Scholar, University of Chicago
    2016American Society of Clinical Oncology Pediatric Oncology Award
    2016Fellow of the American Society of Clinical Oncology (FASCO)
    2018The Samuel Spector Award for Mentorship, Department of Pediatrics, University of Chicago
    2019AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research , University of Chicago

    Collapse Research 
    Collapse research activities and funding
    U10CA007431     (COHN, SUSAN L)Dec 1, 1978 - Dec 31, 2002
    NIH
    PEDIATRIC ONCOLOGY GROUP
    Role: Principal Investigator
    R29CA051061     (COHN, SUSAN L)Jul 1, 1990 - Jun 30, 1995
    NIH
    MOLECULAR MECHANISMS OF DIFFERENTIATION IN NEUROBLASTOMA
    Role: Principal Investigator
    R03HS007846     (COHN, SUSAN E)Sep 30, 1992 - Sep 29, 1994
    NIH
    VARIATIONS BETWEEN RURAL AND URBAN AIDS CARE
    Role: Principal Investigator
    R01CA074824     (COHN, SUSAN L)Aug 1, 1997 - May 31, 2002
    NIH
    ELAV-LIKE PROTEINS IN NEUROBLASTOMA
    Role: Principal Investigator
    R01NS049814     (COHN, SUSAN L)Jul 1, 2004 - Apr 30, 2009
    NIH
    The Role of SPARC in Neuroblastoma Angiogenesis
    Role: Principal Investigator
    R21NS080120     (COHN, SUSAN L.)Mar 1, 2013 - Feb 28, 2015
    NIH
    Mechanism of SPARC peptide FSEC inhibition of angiogenesis in neuroblastoma
    Role: Principal Investigator
    R21CA173297     (COHN, SUSAN L.)Jul 1, 2013 - Jun 30, 2015
    NIH
    Mechanisms of Pancreatic Cancer Inhibition by SPARC
    Role: Principal Investigator
    UL1TR002389     (SOLWAY, JULIAN)Sep 6, 2017 - Jun 30, 2022
    NIH
    ITM 2.0: Advancing Translational Science in Metropolitan Chicago
    Role: Co-Investigator
         Oct 1, 2017 - Sep 30, 2019
    Alex's Lemonade Stand Foundation
    Genome-Wide 5hmC Profiling of Neuroblastoma Tumors and Patient Cell-free DNA
    Role: Principal Investigator
         Dec 31, 2017 - Dec 30, 2019
    Hyundai Hope on Wheels
    MELK, A New Therapeutic Target for Neuroblastoma
    Role: Principal Investigator
         (Volchenboum, S.L.)Jul 1, 2019 - Jun 30, 2022
    St. Baldrick's Foundation
    Pediatric Cancer Data Commons
    Role Description: Project Goals: The goal of this St. Baldrick’s Consortium Grant is to develop a comprehensive Pediatric Cancer Data Commons to advance pediatric oncology research by harmonizing, collecting, storing, and sharing large amounts of clinical trials data from studies of children with cancer. Specific Aims: 1) Profile available sources of pediatric oncology clinical data and current data standards for pediatric cancer. 2) Establish a data dictionary for pediatric cancer clinical data and harmonize existing data sets. 3) Provide cohort discovery, data access tools and processes, and education and training to the pediatric oncology community.
         (Cohn, S.L.)Jul 1, 2020 - Jun 30, 2022
    Hyundai Hope on Wheels
    Targeting DNA Double Strand Break (DSB) Repair Pathways Neuroblastoma
    Role Description: Project Goals: The overall goal of this study is to target proteins that promote efficient DNA damage repair in neuroblastoma to abrogate treatment resistance and improve the outcome of children with high-risk. Specific Aims: 1) To functionally characterize how MELK, EZH2, and MYCN mediate competent HR DSB repair. 2) To investigate the activity of PARP inhibitors in neuroblastoma cells with HR deficiency due to MELK, EZH2, or MYCN inhibition and treatment resistance in neuroblastoma cells:
    R21-CA259771     (Skapek, S)Apr 2, 2021 - Mar 31, 2023
    NIH/NCI
    Identifying neuroblastoma drivers and bringing them to the clinic
    Role Description: Project Goals: The goal of this project is to identify drivers of aggressive neuroblastoma by integrating copy number and expression analysis. A second aim is to perform functional validation of in silico hits. Specific Aims: 1. To uncover oncogenic drivers and tumor suppressors in neuroblastoma by using iExCN, a Bayesian-based, intregrative analysis algorithm; 2. To experimentally validate iExCN-predicted drivers and tumor suppressors in a panel neuroblastoma cell lines and PDX models; 3. To explore how CNVs and expression of iExCN genes correlate with clinical variables to improve risk stratification models and guide therapy for children with neuroblastoma.
         (Volchenboum, S.L.)Jan 1, 2022 - Dec 3, 2025
    Innovation in Cancer Informatics
    GEARBOx - a multisite clinical trial matching tool for children with relapsed or refractory cancer
    Role Description: Project Goal: The University of Chicago’s Pediatric Cancer Data Commons (PCDC) team has built a platform called GEARBOx (Genomic Eligibility Algorithm at Relapse for Better Outcomes) that enables clinicians to match their acute myelogenous leukemia (AML) patients with open clinical trials for relapsed or refractory disease. In this grant, GEARBOx will be expanded to several other types of pediatric cancer and more efficient ways to extract criteria from trials using natural language processing will be developed. Connections to third parties, such as Foundation Medicine, Inc, will also be established to facilitate the automatic import of genomic biomarkers for faster and more accurate trial matching

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Desai AV, Elmuti L, Cahaney C, De Guzman RM, Streby KA, Cohn SL. Multimodality treatment for recurrent neuroblastoma in the central nervous system. Pediatr Blood Cancer. 2023 Jan 31; e30227. PMID: 36720647.
      View in: PubMed
    2. Friedman DN, Goodman PJ, Leisenring WM, Diller LR, Cohn SL, Howell RM, Smith SA, Tonorezos ES, Wolden SL, Neglia JP, Ness KK, Gibson TM, Nathan PC, Weil BR, Robison LL, Oeffinger KC, Armstrong GT, Sklar CA, Henderson TO. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2022 Dec 16; JCO2201732. PMID: 36525618.
      View in: PubMed
    3. Campbell DM, Cowlings PD, Tholanah M, Robinson MJ, Graham G, Aseru S, Dub? K, Cohn SE, Bar KJ, Connick E, Mngqbisa R, Scully EP, Stockman JK, Gianella S. A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research. J Acquir Immune Defic Syndr. 2022 12 15; 91(5):e12-e14. PMID: 36083494.
      View in: PubMed
    4. Hains AE, Uppal S, Cao JZ, Salwen HR, Applebaum MA, Cohn SL, Godley LA. MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074. PMID: 35942521.
      View in: PubMed
    5. Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 12 10; 40(35):4107-4118. PMID: 35839426.
      View in: PubMed
    6. Desai AV, Applebaum MA, Karrison TG, Oppong A, Yuan C, Berg KR, MacQuarrie K, Sokol E, Hall AG, Pinto N, Wolfe I, Mody R, Shusterman S, Smith V, Foster JH, Nassin M, LaBelle JL, Bagatell R, Cohn SL. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977. PMID: 35665495.
      View in: PubMed
    7. Cohn SL, Pearson ADJ. Rethinking high-risk neuroblastoma treatment. Pediatr Blood Cancer. 2022 08; 69(8):e29730. PMID: 35441788.
      View in: PubMed
    8. LaFond CM, Yost A, Lankin K, Kilaru M, Cohn SL. The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for 131I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. J Pediatr Hematol Oncol Nurs. 2022 Sep-Oct; 39(5):304-316. PMID: 36129889.
      View in: PubMed
    9. Mayampurath A, Ramesh S, Michael D, Liu L, Feinberg N, Granger M, Naranjo A, Cohn SL, Volchenboum SL, Applebaum MA. Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clin Cancer Inform. 2021 12; 5:1181-1188. PMID: 34882497.
      View in: PubMed
    10. Plana A, Furner B, Palese M, Dussault N, Birz S, Graglia L, Kush M, Nicholson J, Hecker-Nolting S, Gaspar N, Rasche M, Bisogno G, Reinhardt D, Zwaan CM, Koscielniak E, Frazier AL, Janeway K, S Hawkins D, Kolb EA, Cohn SL, Pearson ADJ, Volchenboum SL. Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clin Cancer Inform. 2021 09; 5:1034-1043. PMID: 34662145.
      View in: PubMed
    11. Masters MC, Cohn SE. Two-drug HIV regimens: more data still needed. Lancet HIV. 2021 08; 8(8):e454-e455. PMID: 34358493.
      View in: PubMed
    12. Kawano A, Hazard FK, Chiu B, Naranjo A, LaBarre B, London WB, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2021 08 01; 45(8):1075-1081. PMID: 33739795.
      View in: PubMed
    13. Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021 10 10; 39(29):3229-3241. PMID: 34319759.
      View in: PubMed
    14. DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, Villablanca JG, Vo KT, Pinto N, Mosse YP, Maris JM, Shusterman S, Cohn SL, Goldsmith KC, Weiss B, Yanik GA, Twist CJ, Irwin MS, Haas-Kogan DA, Park JR, Marachelian A, Matthay KK. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021 11 01; 39(31):3506-3514. PMID: 34270348.
      View in: PubMed
    15. Balyasny S, Lee SM, Desai AV, Volchenboum SL, Naranjo A, Park JR, London WB, Cohn SL, Applebaum MA. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 07 01; 4(7):e2116248. PMID: 34236408.
      View in: PubMed
    16. Bao R, Spranger S, Hernandez K, Zha Y, Pytel P, Luke JJ, Gajewski TF, Volchenboum SL, Cohn SL, Desai AV. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. J Immunother Cancer. 2021 07; 9(7). PMID: 34272305.
      View in: PubMed
    17. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, Hank JA, Batova A, London WB, Tenney SC, Smith M, Shulkin BL, Parisi M, Matthay KK, Cohn SL, Maris JM, Bagatell R, Park JR, Sondel PM. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021 04 15; 27(8):2179-2189. PMID: 33504555.
      View in: PubMed
    18. Moreno L, Guo D, Irwin MS, Berthold F, Hogarty M, Kamijo T, Morgenstern D, Pasqualini C, Ash S, Potschger U, Ladenstein R, Valteau-Couanet D, Cohn SL, Pearson ADJ, London WB. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2021 03; 68(3):e28794. PMID: 33205902.
      View in: PubMed
    19. Liang WH, Federico SM, London WB, Naranjo A, Irwin MS, Volchenboum SL, Cohn SL. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform. 2020 10; 4:895-905. PMID: 33058692.
      View in: PubMed
    20. Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Reply to K. Beiske et al. J Clin Oncol. 2020 11 01; 38(31):3720-3721. PMID: 32931402.
      View in: PubMed
    21. Ambros IM, Tonini GP, P?tschger U, Gross N, Mosseri V, Beiske K, Berbegall AP, B?nard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Valteau-Couanet D, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson ADJ, Ambros PF. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. J Clin Oncol. 2020 11 01; 38(31):3685-3697. PMID: 32903140.
      View in: PubMed
    22. Barr EK, Laurie K, Wroblewski K, Applebaum MA, Cohn SL. Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatr Blood Cancer. 2020 10; 67(10):e28390. PMID: 32710697.
      View in: PubMed
    23. Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL, London WB. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2020 08; 67(8):e28359. PMID: 32472746.
      View in: PubMed
    24. Gerstle K, Siddiqui A, Schulte JJ, Cohn SL. Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. Pediatr Blood Cancer. 2020 08; 67(8):e28218. PMID: 32472953.
      View in: PubMed
    25. Mack JW, Uno H, Twist CJ, Bagatell R, Rosenberg AR, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park JR, Cohn SL, Fernandez JH, Diller LR, Shusterman S. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. PMID: 32360991.
      View in: PubMed
    26. Sokol E, Desai AV, Applebaum MA, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A, Volchenboum S, Cohn SL, London WB. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol. 2020 06 10; 38(17):1906-1918. PMID: 32315273.
      View in: PubMed
    27. Applebaum MA, Barr EK, Karpus J, West-Szymanski DC, Oliva M, Sokol EA, Zhang S, Zhang Z, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman RL, Godley LA, Stranger BE, He C, Cohn SL. 5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clin Cancer Res. 2020 03 15; 26(6):1309-1317. PMID: 31852832.
      View in: PubMed
    28. Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133. PMID: 31812554.
      View in: PubMed
    29. Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol. 2019 Dec; 12(12):1129-1143. PMID: 31774001.
      View in: PubMed
    30. Mack JW, Cronin AM, Uno H, Shusterman S, Twist CJ, Bagatell R, Rosenberg A, Marachelian A, Granger MM, Glade Bender J, Baker JN, Park J, Cohn SL, Levine A, Taddei S, Diller LR. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. PMID: 31584705.
      View in: PubMed
    31. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. PMID: 31454045.
      View in: PubMed
    32. Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255. PMID: 31386611.
      View in: PubMed
    33. Kemp CG, Lipira L, Huh D, Nevin PE, Turan JM, Simoni JM, Cohn SE, Bahk M, Berzins B, Andrasik M, Mugavero MJ, Rao D. HIV stigma and viral load among African-American women receiving treatment for HIV. AIDS. 2019 07 15; 33(9):1511-1519. PMID: 31259767.
      View in: PubMed
    34. Applebaum MA, Barr EK, Karpus J, Nie J, Zhang Z, Armstrong AE, Uppal S, Sukhanova M, Zhang W, Chlenski A, Salwen HR, Wilkinson E, Dobratic M, Grossman R, Godley LA, Stranger BE, He C, Cohn SL. 5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. JCO Precis Oncol. 2019; 3. PMID: 31179414.
      View in: PubMed
    35. Braunstein SE, London WB, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C, Park JR, La Quaglia MP, Haas-Kogan DA. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. PMID: 30968542.
      View in: PubMed
    36. Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. Mol Cancer Ther. 2019 03; 18(3):507-516. PMID: 30674566.
      View in: PubMed
    37. Naranjo A, Irwin MS, Hogarty MD, Cohn SL, Park JR, London WB. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2018 12; 2:1-15. PMID: 30652588.
      View in: PubMed
    38. Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, London WB, Irwin MS. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 04; 66(4):e27556. PMID: 30479064.
      View in: PubMed
    39. Twist CJ, Naranjo A, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, London WB, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124. PMID: 30444686.
      View in: PubMed
    40. Sokol EA, Engelmann R, Kang W, Pinto N, Starkey A, Lai H, Nadel H, Shulkin BL, Pu Y, Appelbaum D, Yanik GA, Cohn SL, Armato SG, Volchenboum S. Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417. PMID: 30198643.
      View in: PubMed
    41. DuBois SG, Mosse YP, Fox E, Kudgus RA, Reid JM, McGovern R, Groshen S, Bagatell R, Maris JM, Twist CJ, Goldsmith K, Granger MM, Weiss B, Park JR, Macy ME, Cohn SL, Yanik G, Wagner LM, Hawkins R, Courtier J, Lai H, Goodarzian F, Shimada H, Boucher N, Czarnecki S, Luo C, Tsao-Wei D, Matthay KK, Marachelian A. Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149. PMID: 30093449.
      View in: PubMed
    42. Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. Oncotarget. 2018 Jan 19; 9(5):6416-6432. PMID: 29464082.
      View in: PubMed
    43. Nassin ML, Nicolaou E, Gurbuxani S, Cohn SL, Cunningham JM, LaBelle JL. Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. Biol Blood Marrow Transplant. 2018 03; 24(3):452-459. PMID: 29191664.
      View in: PubMed
    44. de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018 01; 2(1):25-34. PMID: 29376112.
      View in: PubMed
    45. Erbe AK, Wang W, Carmichael L, Kim K, Mendon?a EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196. PMID: 28972044.
      View in: PubMed
    46. Hungate EA, Applebaum MA, Skol AD, Vaksman Z, Diamond M, McDaniel L, Volchenboum SL, Stranger BE, Maris JM, Diskin SJ, Onel K, Cohn SL. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. J Natl Cancer Inst. 2017 10 01; 109(10). PMID: 29117357.
      View in: PubMed
    47. Tran L, Fitzpatrick C, Cohn SL, Pytel P. Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. Virchows Arch. 2017 Oct; 471(4):553-557. PMID: 28864906.
      View in: PubMed
    48. Cohn SE. Women in HIV trials: improving adherence and outcomes. Lancet HIV. 2017 12; 4(12):e530-e531. PMID: 28729157.
      View in: PubMed
    49. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587. PMID: 28471719.
      View in: PubMed
    50. Applebaum MA, Desai AV, Glade Bender JL, Cohn SL. Emerging and investigational therapies for neuroblastoma. Expert Opin Orphan Drugs. 2017; 5(4):355-368. PMID: 29062613.
      View in: PubMed
    51. Secola R, Marachelian A, Cohn SL, Toy B, Neville K, Granger M, Brentlinger A, Martin G. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. J Pediatr Oncol Nurs. 2017 May/Jun; 34(3):160-172. PMID: 28061552.
      View in: PubMed
    52. Volchenboum SL, Cox SM, Heath A, Resnick A, Cohn SL, Grossman R. Data Commons to Support Pediatric Cancer Research. Am Soc Clin Oncol Educ Book. 2017; 37:746-752. PMID: 28561664.
      View in: PubMed
    53. Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, Salwen H, Cohn SL, Bown N, Tweddle DA. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget. 2016 Dec 27; 7(52):87301-87311. PMID: 27888620.
      View in: PubMed
    54. Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2017 02; 72:177-185. PMID: 28033528.
      View in: PubMed
    55. Chlenski A, Dobratic M, Salwen HR, Applebaum M, Guerrero LJ, Miller R, DeWane G, Solomaha E, Marks JD, Cohn SL. Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget. 2016 Nov 22; 7(47):77696-77706. PMID: 27776337.
      View in: PubMed
    56. Applebaum MA, Jha AR, Kao C, Hernandez KM, DeWane G, Salwen HR, Chlenski A, Dobratic M, Mariani CJ, Godley LA, Prabhakar N, White K, Stranger BE, Cohn SL. Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget. 2016 Nov 22; 7(47):76816-76826. PMID: 27765905.
      View in: PubMed
    57. Sokol E, Huang E, Pytel P, Cohn SL, Pinto N. Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. Pediatr Blood Cancer. 2017 03; 64(3). PMID: 27663277.
      View in: PubMed
    58. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma:?A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016 09; 65:1-10. PMID: 27434878.
      View in: PubMed
    59. Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56. PMID: 27092812.
      View in: PubMed
    60. Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL. Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer. 2016 Jun; 63(6):1019-23. PMID: 26864375.
      View in: PubMed
    61. Bagatell R, Cohn SL. Genetic discoveries and treatment advances in neuroblastoma. Curr Opin Pediatr. 2016 Feb; 28(1):19-25. PMID: 26576010.
      View in: PubMed
    62. Marachelian A, Desai A, Balis F, Katzenstein H, Qayed M, Armstrong M, Neville KA, Cohn SL, Bush M, Gunawan R, Lim AP, Smith MA, Smith LM. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol. 2016 Feb; 77(2):405-12. PMID: 26791869.
      View in: PubMed
    63. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015 Sep 20; 33(27):3008-17. PMID: 26304901.
      View in: PubMed
    64. Cohn SL. A Selfless Act. J Clin Oncol. 2015 Nov 10; 33(32):3834-5. PMID: 26261250.
      View in: PubMed
    65. Darlington WS, Pinto N, Hecktman HM, Cohn SL, LaBelle JL. Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma. Pediatr Blood Cancer. 2015 Dec; 62(12):2232-4. PMID: 26174546.
      View in: PubMed
    66. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63. PMID: 26035700.
      View in: PubMed
    67. DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen E, Giacomini K, Weiss B, Cohn SL, Granger MM, Yanik GA, Hawkins R, Courtier J, Jackson H, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei D, Villablanca JG, Marachelian A, Matthay KK. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21. PMID: 25695691.
      View in: PubMed
    68. Applebaum MA, Henderson TO, Lee SM, Pinto N, Volchenboum SL, Cohn SL. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer. 2015 Jan; 62(1):128-33. PMID: 25251613.
      View in: PubMed
    69. Teshiba R, Kawano S, Wang LL, He L, Naranjo A, London WB, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H. Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group. Pediatr Dev Pathol. 2014 Nov-Dec; 17(6):441-9. PMID: 25207821.
      View in: PubMed
    70. Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76. PMID: 25154816.
      View in: PubMed
    71. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Nov; 61(11):1932-9. PMID: 25044743.
      View in: PubMed
    72. Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger RH, Cohn SL, Nanduri J, Verma A, Prabhakar NR, Godley LA. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep. 2014 Jun 12; 7(5):1343-1352. PMID: 24835990.
      View in: PubMed
    73. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database. J Clin Oncol. 2014 Apr 20; 32(12):1228-35. PMID: 24663047.
      View in: PubMed
    74. Martin A, Schneiderman J, Helenowski IB, Morgan E, Dilley K, Danner-Koptik K, Hatahet M, Shimada H, Cohn SL, Kletzel M, Hijiya N. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer. 2014 Aug; 61(8):1350-6. PMID: 24634399.
      View in: PubMed
    75. Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, London WB, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients. Clin Pharmacol Ther. 2014 Jun; 95(6):644-52. PMID: 24549002.
      View in: PubMed
    76. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter? system. Mol Oncol. 2014 May; 8(3):669-78. PMID: 24560446.
      View in: PubMed
    77. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer. 2014 Jun; 61(6):990-6. PMID: 24347462.
      View in: PubMed
    78. Pinto N, Cipkala DA, Ladd PE, Pu Y, Cohn SL. Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretenoin alone or observation. Pediatr Blood Cancer. 2014 Jun; 61(6):1104-6. PMID: 24293072.
      View in: PubMed
    79. Armstrong AE, Dargart J, Reichek J, Walterhouse DO, Matossian D, Cohn RA, Gosiengfiao Y. Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. Pediatr Blood Cancer. 2014 May; 61(5):949-50. PMID: 24273036.
      View in: PubMed
    80. Moss? YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014 Apr; 61(4):627-35. PMID: 24038992.
      View in: PubMed
    81. Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer. 2013 Oct 15; 119(20):3718-26. PMID: 23901000.
      View in: PubMed
    82. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. PMID: 23890779.
      View in: PubMed
    83. Kirby C, Ambros PF, Billiter D, London WB, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. AMIA Jt Summits Transl Sci Proc. 2013; 2013:103. PMID: 24303312.
      View in: PubMed
    84. Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013 Apr; 54(4):541-8. PMID: 23440556.
      View in: PubMed
    85. Seif AE, Naranjo A, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW, von Allmen D, Cohn SL, London WB, Park JR, Diller LR, Grupp SA. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52. PMID: 23334272.
      View in: PubMed
    86. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Mattay KM, Hogarty M. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer. 2013 Jun; 60(6):985-93. PMID: 23255319.
      View in: PubMed
    87. Gamazon ER, Pinto N, Konkashbaev A, Im HK, Diskin SJ, London WB, Maris JM, Dolan ME, Cox NJ, Cohn SL. Trans-population analysis of genetic mechanisms of ethnic disparities in neuroblastoma survival. J Natl Cancer Inst. 2013 Feb 20; 105(4):302-9. PMID: 23243203.
      View in: PubMed
    88. Sokol E, Haut PR, Gosiengfiao Y, Feinstein K, Pytel P, Cohn SL. Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. Pediatr Blood Cancer. 2013 Mar; 60(3):512-4. PMID: 23129137.
      View in: PubMed
    89. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, Diller L, Schmidt ML, Maris JM, Cohn SL, Shamberger RC. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80. PMID: 22964741.
      View in: PubMed
    90. Morales La Madrid A, Nall MB, Ouyang K, Minor A, Raca G, Kent P, Miller I, Schleiermacher G, Janoueix-Lerosey I, Cohn SL. Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatr Blood Cancer. 2013 Feb; 60(2):332-5. PMID: 22997192.
      View in: PubMed
    91. Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, Matthay KK, Ambros P, Cohn SL, Pearson AD. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer. 2012 Oct 09; 107(8):1418-22. PMID: 22976801.
      View in: PubMed
    92. Morales La Madrid A, La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012 Sep; 7(3):199-210. PMID: 22968692.
      View in: PubMed
    93. Ostler KR, Yang Q, Looney TJ, Zhang L, Vasanthakumar A, Tian Y, Kocherginsky M, Raimondi SL, DeMaio JG, Salwen HR, Gu S, Chlenski A, Naranjo A, Gill A, Peddinti R, Lahn BT, Cohn SL, Godley LA. Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 2012 Sep 15; 72(18):4714-23. PMID: 22815530.
      View in: PubMed
    94. Suganuma R, Wang LL, Sano H, Naranjo A, London WB, Seeger RC, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, Jarzembowski JA, Joshi VV, Navarro S, Peuchmaur M, Shimada H. Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2013 Mar; 60(3):363-70. PMID: 22744966.
      View in: PubMed
    95. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012 May 20; 30(15):1842-8. PMID: 22529259.
      View in: PubMed
    96. Zage PE, Louis CU, Cohn SL. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatr Blood Cancer. 2012 Jul 01; 58(7):1099-105. PMID: 22378620.
      View in: PubMed
    97. Morales La Madrid A, Volchenboum S, Gastier-Foster JM, Pyatt R, Liu D, Pytel P, Lavarino C, Rodriguez E, Cohn SL. Locoregional MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 2012 Oct; 59(4):736-8. PMID: 22213566.
      View in: PubMed
    98. Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, Salwen HR, Maitland ML, Cohn SL. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012 Oct; 59(4):642-7. PMID: 22147414.
      View in: PubMed
    99. Angelini P, London WB, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S. Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: a report from the INRG project. Eur J Cancer. 2012 May; 48(8):1185-91. PMID: 22137163.
      View in: PubMed
    100. Cohn S. Advances in the treatment of neuroblastoma. Clin Adv Hematol Oncol. 2011 Nov; 9(11):865-7. PMID: 22252619.
      View in: PubMed
    101. Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Nov 20; 29(33):4351-7. PMID: 22010014.
      View in: PubMed
    102. Taggart DR, London WB, Schmidt ML, DuBois SG, Monclair TF, Nakagawara A, De Bernardi B, Ambros PF, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64. PMID: 21969516.
      View in: PubMed
    103. Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 01; 17(21):6858-66. PMID: 21908574.
      View in: PubMed
    104. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst. 2011 Aug 17; 103(16):1236-51. PMID: 21799180.
      View in: PubMed
    105. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T, Matthay KK. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011 Aug 20; 29(24):3286-92. PMID: 21768459.
      View in: PubMed
    106. Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011 Oct; 261(1):243-57. PMID: 21586679.
      View in: PubMed
    107. Morales La Madrid A, Rubin CM, Kohrman M, Pytel P, Cohn SL. Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma. Pediatr Blood Cancer. 2012 Mar; 58(3):472-4. PMID: 21480475.
      View in: PubMed
    108. Kakodkar NC, Peddinti R, Kletzel M, Tian Y, Guerrero LJ, Undevia SD, Geary D, Chlenski A, Yang Q, Salwen HR, Cohn SL. The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. Pediatr Blood Cancer. 2011 Jan; 56(1):164-7. PMID: 20860039.
      View in: PubMed
    109. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13. PMID: 21115869.
      View in: PubMed
    110. Moroz V, Machin D, Faldum A, Hero B, Iehara T, Mosseri V, Ladenstein R, De Bernardi B, Rubie H, Berthold F, Matthay KK, Monclair T, Ambros PF, Pearson AD, Cohn SL, London WB. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011 Mar; 47(4):561-71. PMID: 21112770.
      View in: PubMed
    111. Henderson TO, Bhatia S, Pinto N, London WB, McGrady P, Crotty C, Sun CL, Cohn SL. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 01; 29(1):76-82. PMID: 21098321.
      View in: PubMed
    112. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. PMID: 20921469.
      View in: PubMed
    113. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1313-23. PMID: 20879880.
      View in: PubMed
    114. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010 Sep 30; 363(14):1324-34. PMID: 20879881.
      View in: PubMed
    115. Watts DH, Huang S, Cohn SE, Smith L, Hitti J. Repeat pregnancies among HIV-infected women enrolled in clinical trial PACTG1022. J Acquir Immune Defic Syndr. 2009 Jun 01; 51(2):231-3. PMID: 19465826.
      View in: PubMed
    116. McComsey GA, Kang M, Ross AC, Lebrecht D, Livingston E, Melvin A, Hitti J, Cohn SE, Walker UA. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials. 2008 Mar-Apr; 9(2):126-36. PMID: 18474497.
      View in: PubMed
    117. Livingston EG, Cohn SE, Yang Y, Watts HD, Bardeguez AD, Jones TB, Smith LM, Umbleja T, McComsey GA. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy. Obstet Gynecol. 2007 Aug; 110(2 Pt 1):391-7. PMID: 17666616.
      View in: PubMed
    118. Koletar SL, Williams PL, Wu J, McCutchan JA, Cohn SE, Murphy RL, Lederman HM, Currier JS. Long-term follow-up of HIV-infected individuals who have significant increases in CD4+ cell counts during antiretroviral therapy. Clin Infect Dis. 2004 Nov 15; 39(10):1500-6. PMID: 15546087.
      View in: PubMed
    119. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, Koletar SL, Hafner R, Connick E, Valentine FT, McElrath MJ, Roberts NJ, Currier JS. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis. 2003 Dec 15; 188(12):1794-803. PMID: 14673757.
      View in: PubMed
    Cohn's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (392) concept(s)
    _
    Co-Authors Expand Description
    See all (37) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _